US FDA complete response letters have knocked down rare disease applications relying on confirmatory evidence from sponsors from Biohaven to PTC and Immedica (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
